Abstract
It is now possible to use the new anticoagulants in a variety of indications. There are now available direct thrombin inhibitor dabigatran etexilate and direct Factor Xa inhibitors rivaroxaban and apixaban in the Czech Republic.
All three products are already approved for use in the prevention of thromboembolic complications after orthopedic surgery - total hip and knee and knee arthroplasty. Further indication of the new anticoagulants is the prevention of cardioembolic stroke or systemic embolisation in patients with nonvalvular atrial fibrillation (dabigatran etexilate and rivaroxaban) and also the treatment of venous thrombosis (rivaroxaban).
This review article presents the information about their pharmacokinetics and pharmacodynamics, as well as some differences in their effect.